Roche Holding AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The company also has a strong presence in in-vitro diagnostics and is a market leader in this field. Roche is known for its significant investment in research and development, focusing on personalized healthcare and innovative treatments for serious diseases.
Global strategic direction, core research and development leadership, corporate governance, and administrative functions for Roche's worldwide operations.
The Roche Towers (Bau 1 and Bau 2) are iconic modern skyscrapers designed by Herzog & de Meuron, dominating the Basel skyline and reflecting the company's modernity. The campus includes state-of-the-art research labs and historical buildings.
Roche's Basel headquarters fosters a highly scientific, innovative, and collaborative environment. There's a strong emphasis on research, precision, and a long-term perspective. Employees often describe it as international, with a focus on work-life balance supported by Swiss cultural norms.
As the birthplace and global nerve center of Roche, the Basel headquarters is crucial for its strategic decision-making, innovation pipeline, and maintaining its position as a global leader in pharmaceuticals and diagnostics.
Roche supports a wide array of functions globally, including research and development, manufacturing, sales and marketing for its pharmaceuticals and diagnostics divisions, clinical trial operations, regulatory affairs, and extensive customer support services. The company operates in over 100 countries with major R&D and manufacturing sites across North America, Europe, and Asia.
Grenzacherstrasse 124
Basel
Basel-Stadt
Switzerland
Address: 1 DNA Way, South San Francisco, CA 94080, USA
Serves as Roche's primary hub for biotech innovation and operations in North America, driving significant portions of its pharmaceutical pipeline.
Address: Nonnenwald 2, 82377 Penzberg, Germany
Key European hub for integrated research, development, and production across both Roche divisions, significantly contributing to its global supply chain and innovation.
Address: Building 5, Lane 1387, Zhang Dong Road, Pudong, Shanghai, China
Drives Roche's growth and innovation in the rapidly expanding Chinese and broader APAC healthcare markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Roche' leadership includes:
Roche has been backed by several prominent investors over the years, including:
Roche has seen key leadership transitions, notably with Thomas Schinecker becoming CEO in March 2023, and subsequent appointments for divisional CEO roles.
Discover the tools Roche uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Roche commonly uses the [first].[last]@roche.com email format for its employees. Variations might exist based on region or department, but this is the most widely recognized pattern.
[first].[last]@roche.com
Format
jane.doe@roche.com
Example
95%
Success rate
Roche News • 2024-05-21
Roche announced new and updated data from across its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Key results from the phase III ALINA study showed Alecensa (alectinib) reduced the risk of disease recurrence or death by an unprecedented 76% compared to platinum-based chemotherapy in people with anaplastic lymphoma kinase (ALK)-positive early-stage non-small cell lung cancer (NSCLC) after tumour resection....more
Roche News • 2024-04-17
Roche reported solid Q1 2024 results with Group sales increasing by 2% at constant exchange rates. Pharmaceuticals Division sales grew by 2%, driven by newer medicines. Diagnostics Division sales also saw a 2% increase, primarily due to strong immunodiagnostics performance. The company confirmed its outlook for the full year....more
Roche News • 2024-03-13
Roche announced it has entered into an agreement to acquire select assets related to LumiraDx's Point of Care (PoC) diagnostics platform technology. This acquisition aims to strengthen Roche’s diagnostics portfolio and expand its offerings in the PoC segment, providing healthcare professionals with faster and more convenient testing options....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Roche, are just a search away.